Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 12418 matches for

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Vial of the ChadOx (ChAdOx1 nCoV-2019) vaccine. Photo credit: John Cairns © John Cairns

Sign up to our newsletter

Sign up to our newsletter to receive the latest news, insights and events directly to your inbox.

Participant Interest Form

Online induction completion

Join our research community

Join the Restore-B research community for breast reconstruction

SITU Expression of Interest Form

Categories

Similar stories

Oxford’s OrganOx wins the MacRobert Award 2025

The Royal Academy of Engineering has announced that OrganOx has won the £50,000 MacRobert Award, the longest running and most prestigious prize for UK engineering innovation, for its life-saving technology that is supporting more organ transplants and helping to cut waiting lists.

Oxford neurosurgeon secures nearly £2 million for brain cancer trial

Oxford’s OrganOx is shortlisted for the MacRobert Award 2025